Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles

30 May 2025

Abstract excerpt

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants, young children, as well as elderly and immunocompromised patients worldwide. RSV is classified into two major subtypes, RSV-A and RSV-B, and remains the most frequently detected pathogen in infants hospitalized with acute respiratory infections. Recent advances have brought both passive and active immunization...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis Research Advances
Share to Pneumonia and Respiratory Infections
Share to Respiratory viral infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40573384
DOI: 10.3390/v17060793

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance ProfilesPMID 40573384Read ↗

Structure-guided design of small-molecule therapeutics against RSV diseaseSemantic proximity Read ↗

Structural Mapping of Surveillance Data Reveals Conservation of NNI Binding Site in RSV L Protein.Semantic proximity Read ↗

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA VirusesSemantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

Complete definition of how antibodies used to prevent RSV are affected by F mutationsSemantic proximity Read ↗

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.Semantic proximity Read ↗

Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.Semantic proximity Read ↗

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.Semantic proximity Read ↗

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.Semantic proximity Read ↗

Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.Semantic proximity Read ↗

Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolatesSemantic proximity Read ↗

Structural basis for varying drug resistance of SARS-CoV-2 Mpro E166 variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.